What are the clinical, pathological, and molecular characteristics of inflammatory myofibroblastic tumor?

Inflammatory Myofibroblastic Tumor Characteristics

Inflammatory myofibroblastic tumors (IMTs) are locally aggressive mesenchymal neoplasms with a median age at diagnosis of 9 years in children, characterized by myofibroblastic spindle cell proliferation with prominent inflammatory infiltrate, ALK gene fusions in 50-60% of cases, and excellent response rates (>80%) to crizotinib in ALK-positive tumors. 1

Clinical Characteristics

Age and Location Distribution

• Pediatric patients: Median age 9 years, with soft tissue and visceral tumors predominating 1
• Adult patients: Median age 31-46.5 years, with lung involvement more common 1, 2, 3
• Most common sites:
  • Children: Soft tissue and visceral locations
  • Adults: Lungs (20.8%), abdomen (41.7%), intestinal tract, extremities (29.2%), retroperitoneum 1, 2, 3

Biological Behavior

• Locally aggressive with infiltrative growth patterns 1, 4
• Metastases are rare (<5% of cases) 1
• Local recurrence occurs in 25% of children with extrapulmonary IMT 1
• Intermediate biological potential - can exhibit local invasion but distant spread is uncommon 4, 5

Pathological Characteristics

Histologic Features

IMTs display three characteristic histologic patterns 5:

• Fasciitis-like pattern: Loose myxoid stroma with inflammatory cells
• Compact spindle cell pattern: Dense fascicles of spindle cells with marked chronic inflammation and plump atypical myofibroblastic cells 1
• Hypocellular fibrous pattern: Collagenous stroma with scattered inflammatory cells

Inflammatory Component

• Abundant inflammatory infiltrate composed of:
  • Plasma cells (prominent)
  • Lymphocytes
  • Eosinophils 4
• Macrophage infiltration identified in tumor microenvironment 6

Immunohistochemistry

• ALK expression by IHC in 50-60% of cases 1
• Variable expression of smooth muscle actin and other myofibroblastic markers 4

Molecular Characteristics

ALK-Positive IMTs (50-60%)

ALK gene fusions are the hallmark molecular alteration 1, 7:

• Common fusion partners: TPM3, DCTN1, EML4 6
• Clinical significance: Predicts excellent response to crizotinib (>80% response rate) 1, 7
• Diagnostic confirmation: ALK IHC followed by FISH for verification 6

ALK-Negative IMTs (40-50%)

Alternative tyrosine kinase fusions occur in ALK-negative cases 1:

• NTRK fusions (rare but important) - respond to NTRK inhibitors (entrectinib, larotrectinib) 1, 8, 9, 6
• Worse prognosis: ALK-negative IMTs account for all metastatic cases in some series 1
• Molecular testing essential: NGS recommended for all IMT cases to identify targetable alterations 3

Important Caveat

IMT-like morphology can be seen in association with infantile fibrosarcoma harboring TRK fusions, and the relationship between these entities remains unclear 1. This underscores the critical importance of comprehensive molecular testing.

Clinical Outcomes and Prognostic Factors

Survival Data

• Median progression-free survival: 20.8 months 2
• Median overall survival: 43.5 months 2
• Disease progression: Occurs in approximately 58% of patients 2

Prognostic Indicators

Favorable prognostic factors:

• R0 surgical resection - strongest predictor of favorable outcomes 2
• ALK-positive status - predicts response to targeted therapy 1

Adverse prognostic factors:

• ALK-negative status - associated with higher metastatic potential 1
• Hypoalbuminemia - associated with reduced overall survival 2
• Incomplete surgical resection

Treatment Implications

Surgical Management

• Complete surgical resection is curative in most cases but can be associated with significant morbidity 1
• R0 resection achieved in approximately 73.7% of surgical cases 2
• Surgery performed in 79-90% of patients 2, 3

Targeted Therapy

ALK-positive IMTs: Crizotinib is highly effective 7, 10, 8:

• Response rates >80% 1
• Consider in unresectable, recurrent, or metastatic disease
• Can be used in preoperative setting for cytoreduction 9

NTRK-rearranged IMTs: NTRK inhibitors (larotrectinib, entrectinib) are standard treatment 8, 9:

• Appropriate for advanced NTRK-rearranged sarcomas
• Can be considered preoperatively when cytoreduction improves morbidity and function

Alternative Therapies

For cases without targetable alterations 9:

• Methotrexate plus vinorelbine/vinblastine show retrospective activity
• Standard sarcoma chemotherapy regimens may be considered

Diagnostic Approach

Essential workup for all IMT cases:

1. Histopathologic confirmation with recognition of characteristic patterns
2. ALK immunohistochemistry as initial screening 6
3. FISH confirmation for ALK-positive cases 6
4. Next-generation sequencing for ALK-negative cases to identify NTRK or other targetable fusions 6, 3
5. Comprehensive imaging to assess extent and resectability

Critical pitfall: Do not rely solely on morphology - molecular testing is mandatory for optimal management and to identify patients who will benefit from targeted therapies rather than surgery alone.